Returning guest, Dr. William Sandborn, MD, Chief of Gastroenterology, Professor of Medicine, University of California, San Diego, discusses positive study results in Crohn’s disease from the IM-UNITI trial on STELARA’S efficacy at five years and the TREMFYA GALAXI-1 trial, Phase 2, week 12 Interim Analyses Data. The GALAXI abstract has been recognized among the three highest scoring UEGW (United European Gastroenterology Week) 2020 abstracts in one of the main categories.
William Sandborn, MD, is a board-certified gastroenterologist who is one of the world’s top experts in the management of ulcerative colitis and Crohn’s disease. He directs the Inflammatory Bowel Disease (IBD) Center at UC San Diego Health. In addition, he is chief of the Division of Gastroenterology, vice chair of clinical operations for the Department of Medicine, and a member of the Clinical Practice Oversight (CPO) Board for UC San Diego Health. A professor in the Department of Medicine at UC San Diego School of Medicine, Dr. Sandborn conducts clinical trials in IBD and leads a team of physicians, research fellows, nurses, and study coordinators. Prior to joining UC San Diego Health, Dr. Sandborn worked in the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minn. Dr. Sandborn completed his fellowship at Mayo Clinic. He did his residency and earned his medical degree at Loma Linda University School of Medicine. He is board-certified in gastroenterology.